Patents Issued in August 13, 2019
-
Patent number: 10376451Abstract: Disclosed are methods of treating and protecting teeth against erosion by use of oral compositions comprising polymeric mineral surface active agents, metal ions such as stannous and zinc and combinations thereof. The present methods provide improved resistance of teeth to erosive demineralization or dissolution and prevention of tooth damage by subsequent exposure of teeth to erosive chemicals such as acidic foods and beverages.Type: GrantFiled: February 26, 2019Date of Patent: August 13, 2019Assignee: The Procter & Gamble CompanyInventors: Arif Ali Baig, Robert Vincent Faller, Donald James White, Jr.
-
Patent number: 10376452Abstract: Provided is a cleansing composition of acyl amino acid, showing good foamability and good lather retention effect, which is rinsed off quickly and affords superior skin texture after drying. A cleansing composition containing the following components (A), (B) and (C), wherein a weight ratio of (A)/(B) is 0.2-5 and a weight ratio of ((A)+(B))/(C) is 2.5-10.0: (A) N-lauroylglycine or a salt thereof (B) N-myristoylglycine or a salt thereof (C) N-acyl acidic amino acid having an acyl group having 8-24 carbon atoms, or a salt thereof.Type: GrantFiled: June 30, 2017Date of Patent: August 13, 2019Assignee: AJINOMOTO CO., INC.Inventors: Rina Yumioka, Kazuhiko Tobita
-
Patent number: 10376453Abstract: Provided is a composition for promoting hair growth, containing, as an active ingredient, a new compound represented by the following formula 1 or a salt thereof, which exhibits an excellent effect of promoting the growth of dermal papilla cells to thereby exhibit the effect of promoting hair growth: Formula 1 wherein R is any one selected from the group consisting of 4-pentenoyl, 10-undecenoyl, isobutyl formate, and 2,4-dihydroxybenzoyl.Type: GrantFiled: May 17, 2019Date of Patent: August 13, 2019Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGYInventors: Hee Jae Shin, Min Ah Lee, Mojid Mondol, Hyi-Seung Lee, Jong Seok Lee, Yeon-Ju Lee
-
Patent number: 10376454Abstract: Agent for the oxidative dyeing of keratinous fibers is provided herein. The agent includes in a cosmetic carrier (A) 1-(2-Hydroxyethyl)-4,5-diaminopyrazole and/or one of the physiologically-tolerated salts thereof. The agent further includes (B) 2,6-dihydroxy-3,4-dimethylpyridine. The agent also includes (C) p-phenylendiamine, toluene-2,5-diamine, 2-(2,5-diaminophenyl)ethanol and/or one of the physiologically-tolerated salts thereof.Type: GrantFiled: May 31, 2016Date of Patent: August 13, 2019Assignee: Henkel AG & Co. KGaAInventors: Constanze Neuba, Burkhard Mueller
-
Patent number: 10376455Abstract: The present disclosure provides biophotonic topical compositions and methods useful in phototherapy. In particular, the biophotonic topical compositions of the present disclosure are substantially resistant to leaching such that very low amounts of chromophore(s) present in the biophotonic composition leach out of the composition. The biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various skin disorders.Type: GrantFiled: July 1, 2016Date of Patent: August 13, 2019Assignee: KLOX TECHNOLOGIES INC.Inventors: Remigio Piergallini, Nikolaos Loupis, Shipra Rastogi
-
Patent number: 10376456Abstract: The invention relates to aqueous, high active, self-preserving composition of mild surfactants which are used to create transparent liquid formulations with pH similar to skin's pH. More specifically, the composition comprise of sodium/potassium acyl isethionate of Formula I and mono potassium acyl glutamate of Formula II with solids content of at least 45 w/w, for personal care formulation that are ultra-mild, with skin pH and transparent.Type: GrantFiled: August 3, 2015Date of Patent: August 13, 2019Assignee: GALAXY SURFACTANTInventors: Arpit Wankhade, Bhagyesh Jagannath Sawant, Pritesh Mhatre, Nirmal Koshti, Pooja Vaidya Kshirsagar, Ashwini Ballal, Anuradha Sharma, Kumar Raunak
-
Patent number: 10376457Abstract: The present invention teaches a hair straightening system including formulations that will safely and effectively straighten curly hair for at least 2-3 months after a single application, despite frequent washings of the hair. Methods for obtaining said formulations are disclosed. Hair straightening systems including shampoo and one or more conditioners are also provided.Type: GrantFiled: February 12, 2016Date of Patent: August 13, 2019Assignee: BEAUTY BIOLABS LLCInventors: Marc Michael Baum, Janelle Marie Baum
-
Patent number: 10376458Abstract: The invention includes methods for reducing or preventing the staining capacity of a compound to a tooth in a mammalian oral cavity, which includes affixing to the tooth surface a degradable film. The film comprises a starch polymer or copolymer that is formed by crosslinking a starch. The film degrades in the oral cavity within about 1 minute to about 70 minutes after affixation. In some embodiments, it may be preferred the crosslinking occurs in the presence of at least one (poly)carboxylic acid. It may be preferred that the starch selected is a retrograde starch, a starch that is chemically or physically modified to be amylase resistant or a starch that is derived naturally but exhibits amylase resistance.Type: GrantFiled: September 14, 2015Date of Patent: August 13, 2019Assignee: Hegemon Enterprises, LLCInventors: Walter Holberg, Rhett M. Silverstein
-
Patent number: 10376459Abstract: The present invention relates to a combination of active agents comprising at least one essential oil, at least one cyclodextrin and at least one liquid fatty substance, the cyclodextrin/essential oil weight ratio ranging from 5 to 12, and to its process of preparation. The present invention also relates to a composition comprising, in a physiologically acceptable medium, such a combination of active agents, and to its process of preparation.Type: GrantFiled: December 19, 2013Date of Patent: August 13, 2019Assignee: L'OREALInventors: Cécile Saquet-Gouville, Olga Biganska, Catherine Marion
-
Patent number: 10376460Abstract: Provided by the present invention is a corrigent composed of a copolymer having a weight average molecular weight of 10,000-5,000,000 and comprising 10-90 mol % of a constitution unit based on 2-(meth)acryloyloxyethylphosphoryl choline, and 90-10 mol % of a (meth)acrylic monomer containing an alkyl group, a (meth)acrylic monomer containing a quaternary ammonium group and a constitution unit based on a (meth)acrylamide monomer. The present invention also provides a composition for mouth cavity containing the corrigent.Type: GrantFiled: June 30, 2016Date of Patent: August 13, 2019Assignee: NOF CORPORATIONInventors: Koji Miyamoto, Nobuyuki Yamamoto, Shunsuke Sakurai, Yoshihisa Shimamura
-
Patent number: 10376461Abstract: Described herein is a polyether polyamide block copolymer as well compositions and products containing the polyether polyamide block copolymer. Methods of making and using the copolymer, the compositions, and products are also described herein.Type: GrantFiled: May 18, 2012Date of Patent: August 13, 2019Assignee: CRODA INTERNATIONAL PLCInventors: Geng Lin, Nancy W. Harman
-
Patent number: 10376463Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.Type: GrantFiled: May 11, 2012Date of Patent: August 13, 2019Assignee: Eyegate Pharmaceuticals, Inc.Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
-
Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
Patent number: 10376464Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.Type: GrantFiled: October 3, 2016Date of Patent: August 13, 2019Assignee: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice -
Patent number: 10376465Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.Type: GrantFiled: September 27, 2016Date of Patent: August 13, 2019Assignee: Pulmatrix Operating Company, Inc.Inventors: Michael M. Lipp, Jean C. Sung
-
Patent number: 10376466Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.Type: GrantFiled: October 4, 2018Date of Patent: August 13, 2019Assignee: MannKind CorporationInventors: Bryan R. Wilson, Marshall Grant
-
Patent number: 10376467Abstract: The invention relates to a process for reconstitution of a solid form of a pharmaceutical composition, comprising the following successive steps: (i) providing the solid form of the pharmaceutical composition in a sealed container, the pressure within the container being an initial pressure (pi,) comprised between 0.5 Pa and 1.2×105 Pa; (ii) at a first time point (t0) introducing the solvent into said sealed container and maintaining the resulting pressure (pr) within the container during a controlled time ?t1; and (iii) at a second time point (t2) increasing the pressure within the container to a controlled pressure (p2) higher than said resulting pressure (pr) until complete reconstitution.Type: GrantFiled: January 20, 2015Date of Patent: August 13, 2019Inventor: Xavier Payet-Burin
-
Patent number: 10376468Abstract: The subject matter of this invention relates to block copolymers (BCPs) and, more particularly, to block copolymers capable of self-assembly into nanoparticles for the delivery of hydrophobic cargos. The BCPs include a hydrophobic block that contains a thioether functional group that is susceptible to oxidation, transforming the solubility of the block from hydrophobic to hydrophilic, thereby releasing the hydrophobic cargo of the nanoparticle.Type: GrantFiled: December 5, 2017Date of Patent: August 13, 2019Assignees: International Business Machines Corporation, Institute of Bioengineering and Nanotechnology, Biomedical Sciences InstituteInventors: Dylan Boday, Willy Chin, Mareva B. Fevre, Jeannette Garcia, James L. Hedrick, Eunice Leong, Nathaniel H. Park, Rudy J. Wojtecki, Yi Yan Yang
-
Patent number: 10376469Abstract: Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.Type: GrantFiled: February 17, 2017Date of Patent: August 13, 2019Assignee: Biosphere Medical, Inc.Inventor: Philippe Reb
-
Patent number: 10376470Abstract: Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.Type: GrantFiled: August 27, 2017Date of Patent: August 13, 2019Assignee: Althera Life Sciences, LLCInventors: Marie Charmaine Dias, Chandir Ramani
-
Patent number: 10376471Abstract: Provided is a dual dosage form capsule, methods for producing and systems for making the same, which can provide dual release of the two dosages. The dual dosage form capsule has a first capsule member containing a first fill material and a second capsule member containing a second fill material. A band couples the first capsule member to the second capsule member and forms a third chamber defined by an inner surface of the band and each cap of the capsule members. An aperture allows fluid into the third chamber causing the band to at least partially dissolve so that the caps of the capsule members are exposed. The caps of the capsule members can dissolve at the same or different rates to control the timing of the release of the first and second fill materials and hence an active ingredient included within the fill material.Type: GrantFiled: July 10, 2018Date of Patent: August 13, 2019Assignee: Gel Cap Technologies, LLCInventor: John Puckett
-
Patent number: 10376472Abstract: Disclosed herein are methods of electrostatically printing a cyclodextrin composition on a substrate, the method including forming an electrostatically printable composition comprising a polymer and one or more cyclodextrins, one or more cyclodextrin inclusion complexes, or a combination thereof, and electrostatically printing the composition on a substrate. Also described are electrostatically printable compositions, methods of making the compositions, printing systems employing the compositions, substrates having the composition electrostatically printed thereon, laminates thereof, and uses of the printed substrates and laminates.Type: GrantFiled: July 12, 2016Date of Patent: August 13, 2019Assignee: Cellresin Technologies, LLCInventors: Willard E. Wood, Joseph S. Keute
-
Patent number: 10376473Abstract: A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.Type: GrantFiled: July 23, 2018Date of Patent: August 13, 2019Assignee: 3M Innovative Properties CompanyInventors: James P. DiZio, Elizabeth E. Johnson, Zheng Z. Wu, Amy Preszler Prince
-
Patent number: 10376474Abstract: A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.Type: GrantFiled: November 8, 2016Date of Patent: August 13, 2019Assignee: TEIKOKU SEIYAKU CO., LTD.Inventors: Kunihiko Matsushita, Mamoru Naruse, Kenichi Hattori
-
Patent number: 10376475Abstract: The present invention relates to a novel method of treatment of acne in a human patient in need thereof, comprising administering topically to said patient an effective amount of the compound 3,5-Dihydroxy-4-isopropyl-trans-stilbene (Compound 1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 9, 2015Date of Patent: August 13, 2019Assignee: DERMAVANT SCIENCES GMBHInventors: Javier Cote-Sierra, Susan H. Smith, Steven M. Frey
-
Patent number: 10376476Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.Type: GrantFiled: March 14, 2018Date of Patent: August 13, 2019Assignees: UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Isabelle Mus-Veteau, Olivier Thomas, Marie-Aude Tribalat, Stephane Azoulay
-
Patent number: 10376477Abstract: The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.Type: GrantFiled: December 12, 2016Date of Patent: August 13, 2019Assignee: Berg LLCInventors: Joaquin J. Jimenez, Niven Rajin Narain, Rangaprasad Sarangarajan, John Patrick McCook
-
Patent number: 10376478Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.Type: GrantFiled: September 12, 2017Date of Patent: August 13, 2019Assignee: The Procter & Gamble CompanyInventors: Richard John Dansereau, Daren K. Anness, David L. Ramsey, Guhan Balan
-
Patent number: 10376479Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.Type: GrantFiled: April 27, 2016Date of Patent: August 13, 2019Assignee: Jina Pharmaceuticals, Inc.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 10376480Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.Type: GrantFiled: May 10, 2018Date of Patent: August 13, 2019Assignee: ImmunoMet Therapeutics Inc.Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
-
Patent number: 10376481Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.Type: GrantFiled: January 9, 2017Date of Patent: August 13, 2019Assignee: ARDELYX, INC.Inventors: Noah Bell, Christopher Carreras, Michael Robert Leadbetter, Jason Gustaf Lewis, Jeffrey W. Jacobs, Irina Dotsenko, Dean Dragoli, Ying He, Andrew King, Matthew Siegel
-
Patent number: 10376482Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.Type: GrantFiled: June 21, 2016Date of Patent: August 13, 2019Inventor: Franco Cavaleri
-
Patent number: 10376483Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: GrantFiled: May 9, 2018Date of Patent: August 13, 2019Assignee: Glykon Technologies Group, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Patent number: 10376484Abstract: The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both bezafibrate and resveratrol or resveratrol derivatives. The combination is more particularly used in the treatment of moderate defects of ?-oxidation of long-chain fatty acids or of the respiratory chain of mitochondria.Type: GrantFiled: December 19, 2014Date of Patent: August 13, 2019Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Universite Paris DescartesInventors: Jean Bastin, Fatima Djouadi
-
Patent number: 10376485Abstract: A method for ameliorating metabolic syndrome may include administering, to a patient in need thereof, an effective amount of a monounsaturated fatty acid having 22 carbons or a salt or an ester thereof and/or an effective amount of a monounsaturated fatty acid having 20 carbons or a salt or an ester thereof.Type: GrantFiled: February 29, 2012Date of Patent: August 13, 2019Assignee: NIPPON SUISAN KAISHA, LTD.Inventors: Zhi-hong Yang, Hiroko Miyahara, Shuhei Takemura, Akimasa Hatanaka
-
Patent number: 10376486Abstract: The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.Type: GrantFiled: February 7, 2017Date of Patent: August 13, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Guochun Jiang, Satya Dandekar
-
Patent number: 10376487Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.Type: GrantFiled: October 10, 2014Date of Patent: August 13, 2019Assignee: Vanda Pharmaceuticals Inc.Inventors: Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
-
Patent number: 10376488Abstract: Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient.Type: GrantFiled: September 5, 2014Date of Patent: August 13, 2019Assignee: ONENESS BIOTECH CO., LTDInventors: Wei-Luen Chang, Mo-Chi Cheng
-
Patent number: 10376489Abstract: A method of treating a chronic wound in a subject in need of such treatment is provided. The method includes administering to the subject at least one antioxidant agent in an amount effective to treat the wound. In some versions, the antioxidant agent is ?-tocopherol or N-acetyl cysteine, or a combination of these compounds. In other versions, a method of preparing a chronic wound animal model is provided.Type: GrantFiled: April 20, 2017Date of Patent: August 13, 2019Assignee: The Regents of the University of CaliforniaInventors: Manuela Martins-Green, Sandeep Dhall, Danh Do, Neal Schiller
-
Patent number: 10376490Abstract: A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid complex capsule preparation and the Pu'er teat/tea product are separately packaged.Type: GrantFiled: March 22, 2016Date of Patent: August 13, 2019Assignee: Tasly Pharmaceutical Group Co., Ltd.Inventors: Naifeng Wu, Xijun Yan, He Sun, Kaijing Yan, Yonghong Zhu, Shunnan Zhang, Xiaolin Bai, Yi He, Xiaohui Ma, Ting Li
-
Patent number: 10376491Abstract: Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.Type: GrantFiled: March 22, 2016Date of Patent: August 13, 2019Assignee: Tasly Pharmaceutical Group Co., Ltd.Inventors: Xijun Yan, Naifeng Wu, He Sun, Kaijing Yan, Yonghong Zhu, Xiaohui Ma, Shunnan Zhang, Changwen Li, Xiaolin Bai, Ting Li, Lei Li, Yi He
-
Patent number: 10376492Abstract: A compound is described that is selected from among macrocyclic lactones for treating and/or preventing a complication from a human papillomavirus infection. The complication to be treated and/or prevented can be selected from among malignant melanomas, skin carcinomas, in situ or invasive carcinomas, epidermoid carcinomas, Bowen's disease, head and neck cancers, upper aerodigestive tract cancers, laryngeal cancers, esophageal cancers, stomach cancers, oral papillomas, pharyngeal papillomas, laryngeal papillomas, esophageal papillomas, lung cancers, intravulval neoplasias, intravaginal neoplasias, intracervical neoplasias, cervical dysplasias, cervical carcinomas, penile cancer, intrapenile neoplasias, and in situ or invasive anal carcinomas.Type: GrantFiled: March 28, 2014Date of Patent: August 13, 2019Assignee: GALDERMA S.A.Inventor: Jean Jacovella
-
Patent number: 10376493Abstract: A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.Type: GrantFiled: August 10, 2016Date of Patent: August 13, 2019Assignee: Qaam Pharmaceuticals, LLCInventor: Steven A. Rich
-
Patent number: 10376494Abstract: The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.Type: GrantFiled: June 4, 2018Date of Patent: August 13, 2019Assignee: Orion CorporationInventors: Olli Törmäkangas, Terhi Heikkinen
-
Patent number: 10376495Abstract: Described herein are compound for the modulation of the G-CSF receptor. The compounds may act as agonists, antagonists, and/or mixed or partial agonists/antagonists of G-CSF. Further provided herein are methods of treating a condition, including, for example, a neurodegenerative disease, by administering a compound as detailed herein.Type: GrantFiled: November 22, 2017Date of Patent: August 13, 2019Assignees: University of South Florida, The United States Government as Represented by the Department of Veterans, H. Lee Moffitt Cancer Center and research Institute Inc.Inventors: Juan Sanchez-Ramos, Vasyl Sava, Shijie Song, Said Sebti
-
Patent number: 10376496Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.Type: GrantFiled: September 9, 2014Date of Patent: August 13, 2019Assignee: Merck, Sharp & Dohme Corp.Inventors: Gopal Krishna, Gurudatt Chandorkar, Elham Hershberger, Benjamin Miller, Alan Xiao
-
Patent number: 10376497Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.Type: GrantFiled: April 20, 2017Date of Patent: August 13, 2019Assignee: INTERMUNE, INC.Inventors: Brad O. Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
-
Patent number: 10376498Abstract: Method for treating a viral infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, comprising a moiety represented by figure (I), wherein R1 is a saturated or unsaturated bivalent hydrocarbon group. Viruses subject to treatment can include HIV and flaviviruses such as west nile, dengue, or hepatitis C virus. Compositions and methods of isolation and purification are also described including from the Red Sea sponge.Type: GrantFiled: October 29, 2015Date of Patent: August 13, 2019Assignee: King Abdullah University of Science and TechnologyInventors: Christian R. Voolstra, Aubrie O'Rourke, Stephan Kremb
-
Patent number: 10376499Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 9, 2018Date of Patent: August 13, 2019Assignee: Entasis Therapeutics LimitedInventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Patent number: 10376500Abstract: The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.Type: GrantFiled: February 17, 2017Date of Patent: August 13, 2019Assignee: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.Inventors: José Agustin Rogelio Magaña Castro, Laura Vázquez Cervantes, Juan Socorro Armendáriz Borunda
-
Patent number: 10376501Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Lumacaftor, or a salt, or derivative thereof together with complexation agents and, optionally, pharmaceutically acceptable excipients; processes for the preparation thereof and pharmaceutical compositions containing them. The complex formulations have improved dissolution and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.Type: GrantFiled: April 25, 2017Date of Patent: August 13, 2019Assignee: Druggability Technologies IP Holdco LimitedInventors: Richárd Balázs Kárpáti, Betti Szabóné Ordasi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, László Molnár, Hristos Glavinas, Zsolt Ötvös, Genovéva Filipcsei